



IFW

PATENT  
Customer No. 22,852  
Attorney Docket No. 08358.0008-00000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
Steffen GOLETZ et al. ) Group Art Unit: Not yet assigned  
)  
Application No.: 10/568,098 ) Examiner: Not yet assigned  
)  
Filed: February 10, 2006 ) Confirmation No: Not yet assigned  
)  
For: TUMOR CELL LINES AND USES )  
THEREOF )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: June 6, 2006

By:   
Leslie A. McDonell  
Reg. No. 34,872

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number

10/568,098

Filing Date

2/10/06

First Named Inventor

Steffen GOLETZ

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket Number

08358.0008

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		WO 94/29469				
		WO 97/00957				
		WO 03/023023				

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		ANDERSON. "Human Gene Therapy". Science, Vol. 256, 1992, pp. 808-813.	
		BRUMMELKAMP, et al. "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells". Science, Vol. 296, 2002, pp. 550-553.	
		ELBASHIR, et al. "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells". Nature, Vol. 411, 2001, pp. 494-498.	
		ISNER, et al. "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb". The Lancet, Vol. 348, 1996, pp. 370-374.	
		NOVINA, et al. "siRNA-directed inhibition of HIV-1 infection". Nature Medicine, Vol. 8, No. 7, 2002, pp. 681-686.	
		OHYAMA, et al. "Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells". The EMBO Journal, Vol. 18, No. 6, 1999, pp. 1516-1525.	
		OHYAMA, et al. "Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides". PNAS, Vol. 99, No. 21, 2002, pp. 13789-13794.	
		OUAGARI, et al. "Glycophorin A Protects K562 Cells from Natural Killer Cell Attack". The Journal of Biological Chemistry, Vol. 270, No. 45, 1995, pp. 26970-26975.	
		OWENS, et al. "Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides". PNAS, Vol. 98, No. 4, 2001, pp. 1471-1476.	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/568,098
				<i>Filing Date</i>	2/10/06
				<i>First Named Inventor</i>	Steffen GOLETZ
				<i>Art Unit</i>	Not yet assigned
				<i>Examiner Name</i>	Not yet assigned
Sheet	2	of	2	<i>Attorney Docket Number</i>	08358.0008

NON PATENT LITERATURE DOCUMENTS			
		PADDISON, et al. "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells". Genes & Development, Vol. 16, 2002, pp. 948-958.	
		SIVANANDHAM, et al. "Cancer Vaccines: Clinical Applications". Principles and Practice of the Biologic Therapy of Cancer, Third Edition, S. Rosenberg, 2000, pp. 632-647, Lippincott Williams & Wilkins, Philadelphia, PA.	
		VERMA, et al. "Gene therapy – promises, problems and prospects". Nature, Vol. 389, 1997, pp. 239-242.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.